Newbury Pharmaceuticals AB
The answer first
Does Newbury Pharmaceuticals beat the market?
Yes, Newbury Pharmaceuticals has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 17% of Nordic stocks
- Quality14
- Value21
- Trend64
No. 140 of 195 in healthcare
Max for seven days
Follow Newbury Pharmaceuticals with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Newbury Pharmaceuticals
Your first answer is free, no account needed.
Do you own Newbury Pharmaceuticals, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Newbury Pharmaceuticals and a few more. Free, no card.
Super Stock+46.4%In short
- Newbury Pharmaceuticals has risen 24.4% over the past year, including dividends.
- Overall, Newbury Pharmaceuticals ranks better than 17% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 87.9%. The price is 84.6% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 17% of Nordic stocks.
No. 140 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 181 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity–
- Asset turnoverSales divided by everything the company owns0.56
- Return on equityProfit divided by equity−116.9%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 96 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity2.9
- P/SPrice divided by sales1.4
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 59 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−20.7%
- 6 months+41.2%
- 9 months+66.1%
- 12 months+24.4%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Newbury Pharmaceuticals
One fund we follow owns Newbury Pharmaceuticals. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Newbury Pharmaceuticals
Newbury Pharmaceuticals AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 7 employees.
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.


See the full analysis of Newbury Pharmaceuticals.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card